In an insightful episode of the Medscape InDiscussion: Cancer Survivorship podcast, Dr. Kathryn J. Ruddy, a Mayo Clinic breast oncologist, engages with Dr. Stacy D’Andre, a medical oncologist specializing in integrative medicine, to explore the evolving role of cannabis and medicinal mushrooms in the care of cancer survivors. Their discussion underscores both potential benefits and current limitations of these emerging therapies.
Understanding Medicinal Mushrooms
Dr. D’Andre opens with an overview of medicinal mushrooms, explaining that these are consumed for their health-promoting effects, in edible or supplemental forms such as teas, powders, and extracts. Notable varieties include reishi, turkey tail, shiitake, maitake, and lion’s mane—each prized for unique immunomodulatory, anti-inflammatory, and antioxidant properties.
Particularly, these mushrooms contain beta‑glucans, polysaccharides recognized for stimulating the immune system. Current investigations include turkey tail’s potential activity in breast cancer as well as trials evaluating reishi for fatigue and joint pain associated with aromatase inhibitor treatment.
In contrast, psilocybin—commonly known as a psychedelic mushroom—is being explored for its effects on treatment-resistant depression and cancer-related anxiety. Despite its Schedule I classification and research hurdles, it shows promise in addressing existential distress and addiction, with ongoing studies across the U.S., including at Mayo Clinic.
Side-Effect Considerations:
- Psilocybin can induce temporary cardiovascular effects (e.g., tachycardia, hypertension) and prolonged psychoactive experiences, necessitating careful monitoring and counseling before and after use.
- Medicinal mushrooms can cause mild gastrointestinal symptoms, and lower blood pressure and glucose. Their immune-stimulating effects prompt caution when combined with immunotherapies; interactions with other medications also require careful oversight.
Hormonal effects appear minimal, as these mushrooms lack estrogenic or androgenic activity.
Cannabis: Current Use in Cancer Care
Roughly 25% to 60% of cancer patients reportedly turn to cannabis for symptom relief, though many do not disclose this to their clinicians. Common uses include managing nausea (especially when other treatments fail), neuropathic pain, and insomnia, though robust data—particularly on appetite stimulation—is lacking.
Effects & Risks:
- Cannabis use may lead to disorientation, impairment of balance, tachycardia, bronchial irritation, or anxiety—especially at higher doses or with inhaled forms.
- Patients may also experience gastrointestinal symptoms or elevated liver enzymes with high-dose CBD, dispelling assumptions about its benign nature.
Clinicians should remain vigilant for drug interactions, such as with warfarin or anticonvulsants, mediated by CYP metabolism pathways; pharmacists can play a key role in guidance and dose adjustments.
Fall risk is a concern, particularly among older or balance-impaired patients. The recommended approach is “start low and go slow”—beginning with minimal THC doses (1–2 mg), and ensuring caregiver support at home.
Barriers and Legal Considerations
Patients may worry about cannabis’s legal status, product quality, and stigma. Even in jurisdictions where medical or recreational use is legal, federal prohibition complicates matters—and travel across state or international borders with cannabis remains inadvisable.
Clinician hesitancy stems from a lack of education, inconsistent legal frameworks, and limited rigorous evidence—exacerbated by the Schedule I classification that hampers large-scale clinical trials.
Resources for Clinicians
To expand their understanding, Dr. D’Andre recommends:
- The Society of Cannabis Clinicians for in-depth cannabis education.
- Healer.com for accessible cannabis-related resources.
- The University of Arizona’s integrative oncology program, which offers modules on mushrooms and psilocybin.
- Mayo Clinic’s upcoming integrative oncology course, covering cannabis and mushrooms in detail.
- Participation in annual psychedelic medicine conferences for emerging insights.
Looking Ahead: Cannabis as Cancer Treatment?
Despite interest, there is currently no high-quality evidence supporting cannabis as an anticancer therapy. Anecdotal reports exist, but foundational questions about dose, formulation, and mechanism remain unanswered, underscoring the need for more research before any therapeutic recommendation can be made.
Conclusion
In summary, cannabis and medicinal mushrooms—including psychedelic variants—are garnering attention in cancer survivorship care. While early findings hint at potential benefits, clinicians and patients alike must navigate a complex landscape, marked by limited evidence, regulatory ambiguity, and open questions about safety.
Further education and research will be essential to transform these promising approaches into well-supported, effective components of integrative oncology.
Dabbin-Dad Newsroom
